ABBV reports positive phase-2b data for Upadacitinib in atopic dermatitis: https://finance.yahoo.com/news/abbvies-upadacitinib-abt-494-meets-120300696.html Upadacitinib (f/k/a ABT-494) is an oral JAK1 inhibitor.